Program: Oral and Poster Abstracts
Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster III
Materials and Methods. There were 8 pts with hemophia, advanced arthropathy and joint bleeding due to synovial overgrowth Standard qualification into RS in each case. Overall 18 RS were done, including 10 ankle, 6 elbow and 2 knee joints. All pts had initial before RS and follow-up study 1-2 months and 3-6 months after RS. All had clinical and US standard examinations, performed by the same physician. In each case the same methods of US imaging were used, including position. All examinations were performed using Aplio 400 with linear transducer (9-12MHz) (Toshiba MSC, J). All images include cine mode collected during examination were reviewed in each case. The final analysis includes an initial study compared to a follow-up of least 2 examinations using a quality scale of intensity of synovial vascularisation, based on SMI and standard evaluation including thickness of synovium, echogenity etc were evaluated.
Results: All RS were without complications. Initial US indicated high vascular flow in affected joints in all pts, in a semiquantitative scale (cSMI 3.1 and mSMI 4.1 ). In the first follow-up cSMI was 2.5 and mSMI was 2.83, in second follow-up studies cSMI 2.56 and mSMI 2.56. There were no other deferrers of imaging analysis, including other US elements of synovial overgrowth reductiona, echogenic improvement etc. Clinical single pt with elbow arthropathy did not respond to RS, which was documented in both cSMI and mSMI, without any differences between initial and follow-up tests. 5 had response a clinical response and 2 had minimal clinical response.
Conclusion: The new Superb Micro-Vascular Imaging technique seems to be useful in the imaging/clinical evaluation of early response in pts with hemophilic arthropathy who had radiosynovectomy. The new US approach with cSMI and mSMI is both high sensitive in detecting of microvascular blood reduction in initial stage of clinical follow-up. Further analysis with higher number of pts and longer follow-up suld be performed to assess real value of this technology
Disclosures: No relevant conflicts of interest to declare.
See more of: Blood Coagulation and Fibrinolytic Factors
See more of: Oral and Poster Abstracts
*signifies non-member of ASH